Search clinical trials for: NOX-E36

Total 21158 results

TME Pharma AG
Profil Institut für Stoffwechselforschung GmbH

Completed

NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
TME Pharma AG

Completed

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

Renal Impairment

Hungary, Moldova, Republic of
TME Pharma AG

Completed

NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Albuminuria

Poland, Germany, Romania, Hungary, Czech Republic
TME Pharma AG

Completed

NOX-E36 First-in-Human (FIH) Study

Type 2 Diabetes Mellitus | Systemic Lupus Erythematosus | Chronic Inflammatory Diseases
COL George Peoples, MD, FACS

Completed

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian Cancer

United States
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

Schizophrenia

Japan
Shanghai Zhimeng Biopharma, Inc.

Recruiting

A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China

Healthy Volunteers

China
Virobay Inc.

Completed

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing (VBY036P1B)

Healthy

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Solid Tumor

United States, Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety, PK and PD Study in Healthy Male Japanese Subjects

Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating SCA-136 Tolerability With Dose Titration and Food

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Schizophrenia

United States
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Shanghai Zhimeng Biopharma, Inc.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

Chronic Hepatitis b
BioSight Ltd.

Completed

Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (BSTPHASE1-01)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Israel
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

Healthy | Alzheimer Disease

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males

Healthy | Alzheimer Disease

Japan
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
University of Guarulhos

Completed

Selective Enamel Etching in Self-etching Adhesives: a 2-year Clinical Trial

Selective Enamel Etching in Dental Restorations
NeuShen Therapeutics

Recruiting

First-into-human Study of NS-136 in Healthy Subjects

Healthy Subjects

Australia
RTI International
National Institute on Drug Abuse (NIDA)

Completed

Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects

Cocaine Dependence

United States
Virobay Inc.

Completed

Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)

Healthy

United States
UCB Pharma

Completed

Rotigotine Restless Legs Syndrome Dose Finding Trial

Idiopathic Restless Leg Syndrome

Germany
Centocor, Inc.

Completed

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Healthy
Takeda

Completed

A Bioequivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Males

Japan
Arbutus Biopharma Corporation

Terminated

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

Chronic Hepatitis

Korea, Republic of, Hong Kong, Thailand, Canada, Australia, Moldova, Republic of, New Zealand, Ukraine
Seattle Children's Research Institute (SCRI)

Terminated

Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

Malaria

United States
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Leiden University
Dutch Cancer Society; ISA Pharmaceuticals; Top Institute Pharma

Completed

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Tumors or Premalignant Lesions

Netherlands
M.D. Anderson Cancer Center

Recruiting

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
Erchonia Corporation

Completed

Study of Low Level Laser Light Therapy on Circumference Reduction

Circumference Reduction

United States
First Affiliated Hospital, Sun Yat-Sen University
Jingchu University of Technology

Unknown

A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

Human Papillomavirus-Related Malignant Neoplasm

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Beta-thalassemia

China
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Beta Thalassemia

Beta-Thalassemia

Greece, Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany
Cerevel Therapeutics, LLC

Terminated

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Substance Use Disorders (SUD)

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

B-Thalassemia

Italy, Greece
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

Lupus Nephritis

United States, Belgium, Mexico, Poland, Netherlands, Thailand

Search clinical trials for: NOX-E36

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations